Main product groups:
Biotec Pharmacon has invested heavily in R&D to create a solid scientific and technological foundation for the manufacture and use of:
Beta-1,3/1,6-glucans that improve the health and well-being of humans:
- Soluble Beta Glucan (SBG): The company’s lead pharmaceutical drug candidate
- Consumer health products for improved immunity: NBG® - Norwegian Beta Glucan
Enzymes in molecular biology, gene technology and DNA-based diagnostics (life science):
- Alkaline phosphatase (SAP): The convenient phosphatase
- Uracil-DNA N-glycosylase (Cod UNG): Ideal for PCR carry-over prevention
- Deoxyribonuclease (Shrimp Nuclease): For selective degradation of dsDNA
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.